Biomarker in Lung Diseases

Lung Diseases Clinical Trial

Official title:

Feasibility Study on Establishing Biomarkers in Lung Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00989846
• Other study ID #: MK02
• Status: Recruiting
• Phase: N/A
• First received: October 5, 2009
• Last updated: October 13, 2009
• Start date: October 2009
• Est. completion date: June 2010

Study information

• Verified date: October 2009
• Source: Heidelberg University
• Contact: Michael Kreuter, MD
• Phone: 49 / 6221 / 396
• Email: michael.kreuter[@]thoraxklinik-heidelberg.de
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Observational

Clinical Trial Summary

Disease related biomarkers have been established decades ago, e.g. blood glucose for diabetes diagnosis and management. Their discovery has grown dramatically during the past decade and they have the potential to lead the physician in diagnosis -especially differential diagnosis - and therapy.

However, a specific serum-biomarker in lung diseases has not been established. Aim of the current study is to to measure lung specific proteins in the serum in patients with various lung diseases and to correlate those with disease severity, lung function and other laboratory results

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: June 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• age >= 18

• acute or chronic lung disease

Exclusion Criteria:

• HIV

• lactation or gestation

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Lung Diseases

Intervention

Other:
• biomarker
measuring serum-biomarkers

Locations

Country	Name	City	State
Germany	Thoraxklinik Heidelberg, Dept. of Pneumology and Respiratory Critical care	Heidelberg

Sponsors (1)

Lead Sponsor	Collaborator
Heidelberg University

Country where clinical trial is conducted

Germany, 

References & Publications (2)

Tzouvelekis A, Kouliatsis G, Anevlavis S, Bouros D. Serum biomarkers in interstitial lung diseases. Respir Res. 2005 Jul 21;6:78. Review. — View Citation

Tzouvelekis A, Pneumatikos I, Bouros D. Serum biomarkers in acute respiratory distress syndrome an ailing prognosticator. Respir Res. 2005 Jun 22;6:62. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum biomarker expression		1 month	No